Medtronic Statement Regarding FDA Circulatory System Devices Panel - Vascular Disease Management

Medtronic Statement Regarding FDA Circulatory System Devices Panel  Vascular Disease Management

DUBLIN - June 22, 2019 - Medtronic plc issued the following statement regarding the U.S. Food and Drug Administration (FDA) Circulatory System Devices ...



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more